Drug Profile
Research programme: helicobacter pylori infection therapies - aRigen
Alternative Names: ARH-1029Latest Information Update: 30 Jun 2020
Price :
$50
*
At a glance
- Originator aRigen
- Developer aRigen; Taiho Pharmaceutical
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Helicobacter infections